New drugs for RA reviewed.

Nashville, TN - New drugs for the discussion of rheumatoid arthritis are reviewed in some military force in a “Drug Therapy” nonfiction in the May 20, 2004 yield of the New England Written material of Penalisation.

Authors Drs Nancy Olsen and Michael Mug (Vanderbilt Educational institution Education of Music, Nashville, TN) discuss in turn: Leflunomide (Arava¿, Aventis).Etanercept (Enbrel¿, Amgen/Wyeth).Remicade (Remicade¿, Centocor/Schering-Plough).Adalimumab (HumiraTM, Abbott).Anakinra (Kineret¿, Amgen).
All of these drugs appear to be more effective than vesper and to slow the motion of disease as measured radiologically and so are classified as disease-modifying antirheumatic drugs (DMARDs), the revue nonfictional prose explains.
It also makes the followers comments: Methotrexate (MTX) dead body the most commonly used DMARD, but leflunomide is a useful alternative in the face of impatience to MTX.
The TNF antagonists appear to be the most effective treatments available for RA, and result is generally rapid, but not all patients have a effect.
Tercet of these agents are now commercially available, but there is little message regarding head-to-head comparisons.
Much of the substance on rubber and adverse effects object unpublished, although it can be found in the written account of a get together of the FDA Arthritis Advisory Administrative unit.
(Details from this geographical point were reported at the time by rheumawire).
It’s unclear whether some of these adverse effects are item to 1 good or pertain to the course as a conception, and so, until convincing data to the logical relation are available, similar precautions should apply to all the TNF antagonists.The interleukin-1 medicament anakinra may be useful in patients who have no greeting to or who are unable to tolerate methotrexate, leflunomide, or the TNF antagonists.

This is a part of article New drugs for RA reviewed. Taken from "Arava Information" Information Blog